GIBSON DUNN

Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing

Firm News | July 20, 2026

Gibson Dunn is advising Avere Therapeutics, Inc. on its reverse merger transaction with NextCure, Inc. (NASDAQ: NXTC) and concurrent $320 million private financing of shares of common stock and pre-funded warrants to a syndicate of healthcare investors. Upon completion of the transaction, the combined company plans to operate under the name Avere Therapeutics, Inc. and trade on Nasdaq under a new ticker symbol.

The Gibson Dunn corporate team is led by partners Ryan Murr and Branden Berns and includes of counsel Evan Shepherd.

Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

Related Capabilities

Mergers and Acquisitions